Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
DiGeorge syndrome, also designated 22q11.2 deletion syndrome (22q11.2DS) in GeneReviews literature, is caused by a microdeletion of chromosome 22q11.2 and represents the most frequently occurring chromosomal microdeletion syndrome. According to GeneReviews, the mean annual incidence was 14.1 per 100,000 live births in a population-based Swedish study; a US population-based study found an overall prevalence of approximately 1:6,000 in whites, blacks, and Asians, and 1:3,800 in Hispanics. The TBX1 gene, located within the deleted region, is listed in this packet as the associated gene. The syndrome involves highly variable multisystem involvement, encompassing congenital heart defects, palatal abnormalities, immune deficiency from thymic hypoplasia, neurodevelopmental features, and, in many individuals, psychiatric manifestations. Per GeneReviews, penetrance is complete in the majority of individuals with the typical deletion, though expressivity is markedly variable.
Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.
The clinical features of DiGeorge syndrome / 22q11.2DS vary substantially between individuals. Per GeneReviews, congenital heart disease is present in approximately 64% of individuals, with conotruncal defects — including ventricular septal defect, tetralogy of Fallot, interrupted aortic arch, and truncus arteriosus — being the most common cardiac anomalies. Palatal abnormalities, most notably velopharyngeal insufficiency, affect approximately 67% per GeneReviews. Intellectual disability is documented in 80–99% of individuals per HPO data, spanning a range from mild disability to borderline-normal cognition. Immune deficiency arising from thymic hypoplasia or aplasia is a cardinal feature, contributing to recurrent infections. Frequent features (30–79%) per HPO data include recurrent otitis media, recurrent pneumonia, seizures, scoliosis, obesity, and seborrheic dermatitis. Less common features (5–29%) include short stature, microcephaly, asthma, hemiparesis, patellar dislocation, and recurrent sinusitis. Affected organ systems in this packet include blood and immune, ear, growth, nervous system, and respiratory systems. Speech and language delays are described in GeneReviews, and elevated rates of psychiatric disorders — including psychosis in adulthood — are a well-documented long-term feature.
Explore clinical features
Genetic Landscape
Assembled from HGNC gene records, ClinGen gene-disease validity evidence, and ClinVar pathogenic variant data. Validity classifications reflect the strength of published evidence linking each gene to this disease.
DiGeorge syndrome / 22q11.2DS results from deletion of chromosome 22q11.2, a region that includes the TBX1 gene (listed in this packet). The molecular mechanism field is not certified in the current packet. Per GeneReviews, nested deletions within 22q11.2 are often familial and may be associated with reduced penetrance and/or milder expression compared with the typical larger deletion. The typical deletion arises de novo in the majority of cases; however, autosomal dominant inheritance is documented when an affected parent transmits the deletion to offspring. The inheritance field is not certified in the current packet, and inheritance patterns are derived here from GeneReviews genetic counseling content. Per GeneReviews, penetrance is complete for the typical deletion, with the variability in clinical presentation attributed to differences in expressivity rather than penetrance.
Diagnosis
Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.
Per GeneReviews, 22q11.2DS is suspected in individuals presenting with one or more of the following: congenital heart disease — particularly conotruncal defects — palatal abnormalities including velopharyngeal insufficiency, immune deficiency due to thymic hypoplasia, hypocalcemia in the newborn period, and characteristic facial features. Chromosomal microarray analysis is the primary confirmatory test and can detect both typical and atypical deletions within the 22q11.2 region. FISH targeting the 22q11.2 locus has historically been used but may not delineate atypical deletion boundaries. Per GeneReviews, all clinical findings associated with 22q11.2DS can also occur as isolated anomalies in otherwise healthy individuals, making molecular confirmation essential for diagnosis. The diagnostic methods field is not certified in the current packet beyond GeneReviews guidance.
Treatment
Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.
No treatments are FDA-approved specifically for DiGeorge syndrome / 22q11.2DS as an overarching condition. Management is multidisciplinary and guided by the individual's presenting features, per GeneReviews clinical practice guidelines. Orphan drug designations relevant to this condition in the current packet include: fasoracetam monohydrate (designated for 22q11.2 deletion syndrome), metyrosine (designated for velocardiofacial syndrome-associated psychosis), and thymalfasin (designated for DiGeorge anomaly with immune defects). These are investigational designations and do not represent FDA approval for routine clinical use. GeneReviews describes management recommendations encompassing cardiac surgery where indicated for structural heart defects, immunologic monitoring and intervention for thymic insufficiency, calcium supplementation for hypocalcemia, and behavioral and psychiatric management for neurodevelopmental and psychiatric features. Surveillance protocols across ENT, immunology, and other systems are outlined in the GeneReviews surveillance section.
Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.
The prognosis of DiGeorge syndrome / 22q11.2DS is highly variable and depends on the nature and severity of cardiac malformations, the degree of immune compromise, and the extent of neurodevelopmental and psychiatric involvement. Per GeneReviews, penetrance is complete in individuals with the typical deletion, but expressivity ranges from severe multisystem involvement to relatively mild presentations with few detectable features. Cardiac defects requiring surgical intervention are a key determinant of early outcomes. Individuals with 22q11.2DS carry elevated long-term risk for psychiatric disorders, including psychosis in adulthood, per GeneReviews. Cognitive outcomes range from mild intellectual disability to borderline-normal functioning. The natural history field is not certified in the current packet, and longitudinal data are derived from GeneReviews clinical description. Adults require ongoing multisystem surveillance per published guidelines.
Research Landscape
Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.
Eight active clinical trial records are included in this packet for DiGeorge syndrome and overlapping conditions. Recruiting studies include NCT07643896, examining assay development for prenatal and obstetric conditions; NCT07284641, evaluating hematopoietic stem cell transplantation for common variable immunodeficiency; NCT07493096, investigating intensive multimodal neurorehabilitation targeting neuroplasticity in pediatric patients; NCT00768820, studying psychiatric and cognitive phenotypes in velocardiofacial syndrome; and NCT05329935, the congenital athymia patient registry. These records are sourced from ClinicalTrials.gov. Research activity reflects ongoing investigation of the immunologic, cardiac, neurological, and psychiatric dimensions of the 22q11.2 deletion spectrum.
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 1:53 PM UTC
Diseases are connected by shared genes, phenotypes, therapeutic targets, and MONDO disease hierarchy. The Rare badge reflects Kisho's rarity classification — scored from authoritative sources including OMIM, Orphanet, orphan drug designations, clinical trial activity, and published prevalence data.
A case report highlights profound protein-losing enteropathy and gastrointestinal hemorrhage due to intestinal lymphangiectasia in a patient with DiGeorge syndrome. This study contributes to the understanding of gastrointestinal complications associated with this genetic disorder.
Getting a cancer diagnosis is devastating. But a new clinical trials resource is making it easier for both patients and doctors to find information about innovative treatments and technologies for care. One trial, which is open to women ages 18-60, is the "Phase III clinical trial." According to the trial text, it tests whether adding chemotherapy to standard hormone-based treatment improves outcome for certain pre-menopausal women with early-stage breast cancer. As part of the trial, researchers will compare patients who receive chemo plus hormone therapy to those who receive hormone therapy alone, measuring whether the cancer is less likely to return. Every drug and treatment was carefully evaluated and developed with clinical trials, Hunter said. "So if you are receiving a medication, whether that's chemotherapy, a biologic therapy, an immunotherapy, a hormone therapy, regardless of the systematic therapy being used to treat your cancer, whether it's radiation or surgery ... As of May 1, there were 12 results for trials available for the topic of "eyes, ears, nose and throat." There is one study, open to men and women ages 18-100, where researchers are testing whether a gene therapy injected into the salivary glands can safely help people who have long-term dry mouth after radiation start producing more saliva. ... Sometimes clinical trials can feel intimidating or confusing to patients, Baker said. "The more patients understand what is available to them, and the more they help with the navigation of their own treatment, when they are perhaps not responding anymore to the standard therapy, or it's a new cancer diagnosis ... the more they engage with their own record and with the resources, the drugs, and the trials available to them, the longer they live and the better they live," Hunter said. According to a news release, the clinical trials resource, which is available at muhealth.org/clinical-trials, provides a comprehensive listing where patients and their families can access detailed information on a wide range of clinical trials.
Las Vegas Nevada United States As per DelveInsight s assessment globally Netherton Syndrome pipeline constitutes 5 key companies continuously working towards developing 5 Netherton Syndrome treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration ... Las Vegas Nevada United States As per DelveInsight s assessment globally Netherton Syndrome pipeline constitutes 5 key companies continuously working towards developing 5 Netherton Syndrome treatment therapies analysis of Clinical Trials Therapies Mechanism of Action Route of Administration and Developments ... This represents an important milestone as Quoin progresses its therapeutic candidate into late-stage clinical development. • In April 2025, ResVita Bio, a therapeutics company specializing in skin disease treatments, announced that the FDA has granted Orphan Drug Designation to RVB-003 for Netherton Syndrome, a serious and chronic skin disorder. Building on the FDA's earlier Rare Pediatric Disease Designation, this milestone highlights ResVita Bio's innovative continuous protein therapy platform, which delivers sustained drug levels directly to the skin, offering enhanced efficacy and improved safety compared to conventional topical treatments. • Netherton Syndrome companies working in the treatment market are Quoin Pharmaceutical, Boehringer Ingelheim, LifeMax Laboratories, Novartis, Daiichi Sankyo, Quoin Pharmaceuticals, Children's Hospital of Philadelphia, and others, are developing therapies for the Netherton Syndrome treatment • Emerging Netherton Syndrome therapies in the different phases of clinical trials are- QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, and others are expected to have a significant impact on the Netherton Syndrome market in the coming years. • In March 2026, Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late-stage specialty pharmaceutical company focused on rare and orphan diseases, announced a clinical and regulatory update following a constructive Type C meeting with the U.S. Press release - DelveInsight Business Research - Netherton Syndrome Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight - published on openPR.com
FDA approves ScinoPharm Taiwan’s glatiramer acetate injection for relapsing multiple sclerosis, marking the first complex injectable generic approval for this therapy. Additionally, Alkermes receives breakthrough therapy designation for alixorexton, an oral treatment for narcolepsy type 1.
